论文部分内容阅读
目的通过对过敏性紫癜(HSP)患儿进行幽门螺杆菌(Hp)检测,探讨过敏性紫癜的发病与幽门螺杆菌感染的关系。方法 82例过敏性紫癜患儿作为观察组,60例门诊健康体检儿童作为对照组,均进行幽门螺杆菌抗体(Hp-Ig G)检测及14C尿素呼气试验。将51例幽门螺杆菌感染阳性的过敏性紫癜患儿随机分为A组(23例)和B组(28例),A组给予常规治疗,B组在常规治疗的基础上给予抗幽门螺杆菌治疗,疗程均为2周。对治愈患儿随访6个月后,比较临床疗效及复发情况。结果观察组幽门螺杆菌阳性率(62.2%)高于对照组(35.0%),差异有统计学意义(P<0.01)。经过2周的治疗,B组总有效率(92.9%)高于A组(60.9%),差异有统计学意义(P<0.01)。A组10例治愈患儿随访6个月,7例(70.0%)复发;B组19例治愈患儿随访6个月,4例(21.1%)复发;B组复发率低于A组,差异有统计学意义(P<0.01)。结论幽门螺杆菌感染可能是过敏性紫癜发病的诱发因素之一,尤其是腹型过敏性紫癜与幽门螺杆菌感染具有相关性,抗幽门螺杆菌三联疗法可提高过敏性紫癜的临床疗效,降低复发率。
Objective To investigate the relationship between Helicobacter pylori infection and the incidence of Henoch-Schonlein purpura by detecting Helicobacter pylori (Hp) in children with Henoch-Schonlein purpura (HSP). Methods 82 cases of children with Henoch-Schonlein purpura as observation group and 60 outpatients with healthy physical examination as control group were tested for H.pylori antibody (Hp-Ig G) and 14 C urea breath test. 51 cases of H. pylori-positive children with Henoch-Schonlein purpura were randomly divided into group A (n = 23) and group B (n = 28). Group A was given routine treatment. Group B was given routine treatment with anti-Helicobacter pylori Treatment, treatment are 2 weeks. After 6 months of follow-up of cured children, the clinical efficacy and recurrence were compared. Results The positive rate of Helicobacter pylori in observation group (62.2%) was higher than that in control group (35.0%), the difference was statistically significant (P <0.01). After two weeks of treatment, the total effective rate in group B (92.9%) was higher than that in group A (60.9%), with significant difference (P <0.01). A group of 10 cases of children were followed up for 6 months, 7 cases (70.0%) recurrence; B group 19 cases of children were followed up for 6 months, 4 cases (21.1%) recurrence; B group recurrence rate was lower than A group, There was statistical significance (P <0.01). Conclusion Helicobacter pylori infection may be one of the predisposing factors for the pathogenesis of anaphylactoid purpura. In particular, the relationship between H. pylori infection and Helicobacter pylori infection is related. The anti-Helicobacter pylori triple therapy can improve the clinical efficacy of allergic purpura and reduce the relapse rate.